Patents Assigned to CSL Limited
  • IL-11 MUTEINS
    Publication number: 20110300100
    Abstract: The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.
    Type: Application
    Filed: July 25, 2011
    Publication date: December 8, 2011
    Applicant: CSL LIMITED
    Inventor: Manuel BACA
  • IL-11 muteins
    Patent number: 7993637
    Abstract: The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: August 9, 2011
    Assignee: CSL Limited
    Inventor: Manuel Baca
  • Treatment of endothelial dysfunction in diabetic patients
    Patent number: 7956035
    Abstract: A method for the treatment of endothelial dysfunction in a diabetic patient, including both diabetes induced macrovascular disorders and diabetes induced microvascular disorders, comprises administration, preferably parenteral administration, to the patient of an effective amount of high density lipoprotein (HDL).
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: June 7, 2011
    Assignee: CSL Limited
    Inventor: Erik S. G. Stroes
  • TREATMENT OF UVEITIS
    Publication number: 20110110934
    Abstract: The present invention relates generally to the use of antagonists of G-CSF, and/or its receptor (G-CSFR) in the treatment of uveitis. The present invention contemplates, therefore, the inhibition of G-CSF or G-CSFR systemically or locally and/or the down-regulation of expression of a G-CSF or G-CSFR in the treatment of uveitis.
    Type: Application
    Filed: October 8, 2010
    Publication date: May 12, 2011
    Applicant: CSL LIMITED
    Inventors: Ian Peter Wicks, Ian Keith Campbell, Ann Leckie Cornish
  • Papilloma virus vaccine
    Patent number: 7939082
    Abstract: A method of providing papilloma virus like particles which may be used for diagnostic purposes or for incorporation in a vaccine for use in relation to infections caused by papilloma virus. The method includes an initial step of constructing one or more recombinant DNA molecules which each encode papilloma virus L1 protein or a combination of papilloma virus L1 protein and papilloma virus L2 protein followed by a further step of transfecting a suitable host cell with one or more of the recombinant DNA molecules so that virus like particles (VLPs) are produced within the cell after expression of the L1 or combination of L1 and L2 proteins. The VLPs are also claimed per se as well as vaccines incorporating the VLPs.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: May 10, 2011
    Assignees: The University of Queensland, CSL Limited
    Inventors: Ian Frazer, Jian Zhou
  • TREATMENT OF NEUROLOGICAL CONDITIONS
    Publication number: 20110091456
    Abstract: The present invention is directed to a method for treating an inflammatory neurodegenerative condition of the CNS in a subject comprising administering to said subject a G-CSF or G-CSFR inhibiting agent selected from the group consisting of an antibody specific for G-CSF or G-CSFR, a soluble G-CSFR or a G-CSF-binding portion thereof and a 20 to 30 nucleotide sense or antisense molecule targeted to a nucleic acid molecule encoding G-CSF.
    Type: Application
    Filed: September 14, 2010
    Publication date: April 21, 2011
    Applicant: CSL LIMITED
    Inventors: Brent Steven McKenzie, Peter Frederick CURWEN, Eugene MARASKOVSKY
  • METHOD OF ELICITING AN IMMUNE RESPONSE AGAINST PANDEMIC INFLUENZA VIRUS
    Publication number: 20100291146
    Abstract: A method for eliciting or inducing a protective immune response in a subject against a pandemic subtype of influenza virus comprises administering to the subject a composition comprising (i) at least one immunogen of an endemic influenza subtype, and (ii) an immunogen-free immunostimulating complex as adjuvant.
    Type: Application
    Filed: October 9, 2008
    Publication date: November 18, 2010
    Applicant: CSL Limited
    Inventors: Martin Pearse, Steve Rockman, David Ryan
  • Polypeptide fragments comprising c terminal portion of helicobacter catalase
    Patent number: 7786260
    Abstract: An isolated polypeptide and immunogenic fragments thereof are described together with their variants and derivatives as novel immunogenic agents for treating or preventing Helicobacter infection in a mammalian host. The polypeptide comprises a C-terminal portion of a Helicobacter catalase, which portion lacks significant amino acid sequence identity with human catalase, wherein the polypeptide is other than full-length Helicobacter catalase.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: August 31, 2010
    Assignees: CSL Limited, The University of New South Wales
    Inventors: Christopher Vincent Doidge, Elizabeth Ann Webb, Linda Joy Rothel, Phillip Sutton, Stuart Lloyd Hazell
  • Immunogenic complexes and methods relating thereto
    Patent number: 7776343
    Abstract: The present invention relates generally to an immunogenic complex comprising a charged organic carrier and a charged antigen and, more particularly, a negatively charged organic carrier and a positively charged antigen. The complexes of the present invention are useful, inter alia, as therapeutic and/or prophylactic agents for facilitating the induction of a cytotoxic T-lymphocyte response to an antigen.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: August 17, 2010
    Assignee: CSL Limited
    Inventors: John Cooper Cox, Debbie Pauline Drane, Andreas Suhrbier
  • METHOD OF TREATMENT
    Publication number: 20100183544
    Abstract: The present invention relates generally to the field of cancer therapy. More particularly, the present invention provides a method for the treatment of gastrointestinal-type cancers and therapeutic agents useful for same.
    Type: Application
    Filed: October 14, 2009
    Publication date: July 22, 2010
    Applicant: CSL LIMITED
    Inventors: Brendan J. JENKINS, Tracy Lynn PUTOCZKI, Matthias ERNST, Andrew JARNICKI, Brent MCKENZIE
  • High affinity antibody antagonists of interleukin-13 receptor alpha 1
    Patent number: 7754213
    Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: July 13, 2010
    Assignees: Merck & Co., Inc., CSL Limited
    Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
  • Porphyromonas gingivalis polypeptides and nucleotides
    Publication number: 20100034908
    Abstract: The present invention relates to isolated Porphyromonas gingivalis polypeptides and nucleotides. The polypeptides include an amino acid sequence selected from the group consisting of: SEQ. ID. NO. 110; SEQ. ID. NO. 111; SEQ. ID. NO. 112; SEQ. ID. NO. 113; SEQ ID NO: 120; SEQ. ID. NO. 123; SEQ. ID. NO. 124; SEQ. ID. NO. 125; SEQ. ID. NO. 130; SEQ. ID. NO. 131; SEQ. ID. NO. 132; SEQ. ID. NO. 133; SEQ. ID. NO.135; SEQ. ID. NO. 136; SEQ. ID. NO. 137; SEQ. ID. NO. 138; SEQ. ID. NO. 143; SEQ. ID. NO. 144; SEQ. ID. NO. 145; SEQ. ID. NO. 146; SEQ. ID. NO. 147; SEQ. ID. NO. 148; and amino acid sequences at least 95% identical thereto.
    Type: Application
    Filed: March 25, 2009
    Publication date: February 11, 2010
    Applicants: CSL Limited, The University of Melbourne
    Inventors: Bruce C. Ross, Ian G. Barr, Michelle A. Patterson, Catherine T. Agius, Linda J. Rothel, Mai B. Margetts, Dianna M. Hocking, Elizabeth A. Webb
  • TREATMENT OF PULMONARY DISEASE CONDITIONS
    Publication number: 20090324591
    Abstract: The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of pulmonary diseases characterized by or associated with infiltration of neutrophils and complications arising therefrom. The present invention further provides agents and pharmaceutical compositions comprising agents which inhibit the activity of G-CSF or its receptor, interfere with G-CSF signaling and/or which down-regulate expression of G-CSF or its receptor.
    Type: Application
    Filed: August 10, 2007
    Publication date: December 31, 2009
    Applicant: CSL LIMITED
    Inventors: David Eric Crump, Andrew Donald Nash
  • TREATMENT AND PROPHYLAXIS OF TH2 MEDIATED DISORDERS
    Publication number: 20090202533
    Abstract: The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11.
    Type: Application
    Filed: October 23, 2008
    Publication date: August 13, 2009
    Applicants: CSL Limited, Yale University
    Inventors: Manuel BACA, Andrew Donald NASH, Jack A. Elias
  • T helper cell epitopes
    Patent number: 7572454
    Abstract: The present invention provides T helper cell epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: August 11, 2009
    Assignees: CSL Limited, The University of Melbourne
    Inventors: David Charles Jackson, Souravi Ghosh, John Walker
  • CYTOKINE MUTEINS
    Publication number: 20090191148
    Abstract: The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.
    Type: Application
    Filed: October 24, 2008
    Publication date: July 30, 2009
    Applicant: CSL LIMITED
    Inventor: Manuel BACA
  • Methods of manufacturing a product and container
    Patent number: 7556706
    Abstract: A container for a relatively brittle product, such as a haemostatic bandage, including a body and a lid for closing the container to hermetically seal the product therein. A sealing rim of the lid includes a layer of elastomeric material which sealingly engages with a sealing rim of the container body to provide a first, static, seal and a second, dynamic, seal. The elastomeric sealing material extends into the interior of the container beneath the lid to provide an elastomeric formation operative to engage an upper surface of the product within the container so as to apply a resilient bias thereto to hold a lower face of the product against the base of the container. The elastomeric formation thereby acts to inhibit substantial movement of the product within the container.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: July 7, 2009
    Assignee: CSL Limited
    Inventors: Gary Wayne Yewdall, Jillian Louise Isabel Mahon, Paul Murray Malouf, Mark Simon Bayly, Peter Kinglsey Bayly
  • polypeptides and nucleotides
    Patent number: 7544777
    Abstract: The present invention relates to isolated Porphorymonas gingivalis polypeptides and nucleotides. The polypeptides include; an amino acid sequence selected from the group consisting of SEQ. ID. NO. 265 to SEQ. ID. NO. 528, SEQ. ID. NO. 531 and SEQ. ID. NO. 532; or an amino acid sequence at least 85%, preferably at least 95%, identical to an amino acid sequence selected from the group consisting of SEQ. ID. NO. 265 to SEQ. ID. NO. 528, SEQ. ID. NO. 531 and SEQ. ID. NO. 532; or at least 40 amino acids having a contiguous sequence of at least 40 amino acids identical to a contiguous amino acid sequence selected from the group consisting of SEQ. ID. NO. 265 to SEQ. ID. NO. 528, SEQ. ID. NO. 531 and SEQ. ID. NO. 532.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: June 9, 2009
    Assignee: CSL Limited, A.C.N.
    Inventors: Bruce C. Ross, Ian G. Barr, Michelle A. Patterson, Catherine T. Agius, Linda J. Rothel, Mai B. Margetts, Dianna M. Hocking, Elizabeth A. Webb
  • Immunogenic LHRH compositions and methods relating thereto
    Patent number: 7534441
    Abstract: The present invention relates generally to an immunogenic LHRH composition and more particularly to an immunogenic LHRH composition comprising a LHRH C-terminal fragment of at least five amino acids. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns of animals, the achievement of livestock production gains such as increasing growth, decreasing feed conversion ratios or the control of unwanted organoleptic characteristics or the treatment of disorders of the reproductive organs.
    Type: Grant
    Filed: January 3, 2005
    Date of Patent: May 19, 2009
    Assignee: CSL Limited
    Inventor: Michael Kerin McNamara
  • Methods and compositions for inducing innate immune responses
    Publication number: 20090017021
    Abstract: The invention relates to TLR ligand formulations that comprise immune stimulating complexes and their use in inducing innate immunity.
    Type: Application
    Filed: April 17, 2008
    Publication date: January 15, 2009
    Applicants: Coley Pharmaceutical Group, Ltd., CSL Limited
    Inventors: Heather L. Davis, Michael J. McCluskie, Debra P. Drane